ProCE Banner Activity

Asparaginase in AYA and Adult ALL: Expert Discussion of Frequently Asked Questions

Clinical Thought
In this commentary, expert faculty address frequently asked questions on optimizing asparaginase therapy for the treatment of AYA and adult ALL.

Released: August 23, 2022

Expiration: August 22, 2023

No longer available for credit.

Share

Faculty

Emily Curran

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Kjeld Schmiegelow

Kjeld Schmiegelow, MD, DMSci

Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Jazz Pharmaceuticals Inc

Faculty Disclosure

Primary Author

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Emily Curran, MD: consultant/advisor/speaker: Amgen, Incyte, Kite, Pfizer, Servier, Tempus.

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Autolus, Blueprint, Forty Seven, Gilead, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, Takeda; data and safety monitoring board member: Daiichi Sanko, Fibrogen; researcher: AbbVie, Blueprint, GlycoMimetics, Novartis

Kjeld Schmiegelow, MD, DMSci

Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Kjeld Schmiegelow, MD: consultant/advisor/speaker: Jazz, Servier.